Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date: August 28, 2017
Event: Completion of enrollment in a clinical trial for the CaverstemTM procedure, designed to treat erectile dysfunction in patients unresponsive to current treatments.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate event regarding clinical trial progress.
Material Changes
The primary material change reported is the operational milestone of completing patient enrollment for the CaverstemTM clinical trial. No financial changes or comparative period data are disclosed in this report.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The press release furnished as Exhibit 99.1 contains forward-looking statements based on information available as of August 28, 2017.
- Risks: Actual results may differ materially from anticipated outcomes due to various factors, including those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016.
- Management Commentary: Management assumes no duty to update forward-looking statements unless required by applicable securities law.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific details on the clinical trial design and next steps.
- Consult the Form 10-K for the year ended December 31, 2016, to understand the risk factors referenced in this filing.
- Monitor future filings for updates on the safety and efficacy results of the CaverstemTM procedure.
- Verify the Company's current financial status through its most recent quarterly or annual reports, as this 8-K contains no financial figures.